Shandong Bailong Chuangyuan Bio-Tech Co. Ltd. (605016) — Cash Flow Quality Index

Latest as of September 2025: 0.48x

Shandong Bailong Chuangyuan Bio-Tech Co. Ltd. (605016) has a Cash Flow Quality Index of 0.48x as of September 2025. Operating cash flow of CN¥45.11 Million is below net income of CN¥94.84 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore 605016 cash generation efficiency to assess how effectively this company generates cash.

Cash Flow Quality Index

0.48x
Operating CF / Net Income

Operating Cash Flow

CN¥45.11 Million
CNY

Net Income

CN¥94.84 Million
CNY

Data as of

Sep 2025
Most recent filing

Shandong Bailong Chuangyuan Bio-Tech Co. Ltd. Cash Flow Quality Index (2016–2025)

Historical Cash Flow Quality Index for Shandong Bailong Chuangyuan Bio-Tech Co. Ltd. across 10 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check 605016 total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.

Annual Cash Flow Quality Index for Shandong Bailong Chuangyuan Bio-Tech Co. Ltd. (2016–2025)

Year-by-year earnings quality comparison for Shandong Bailong Chuangyuan Bio-Tech Co. Ltd.. For live market cap and the full company financial profile, see Shandong Bailong Chuangyuan Bio-Tech Co. (605016) market capitalisation.

Year Quality Index Operating CF (CNY) Net Income YoY Change
2025 0.37x CN¥135.45 Million CN¥368.55 Million ▼ -70.0%
2024 1.23x CN¥300.89 Million CN¥245.60 Million ▲ +21.5%
2023 1.01x CN¥194.63 Million CN¥193.00 Million ▲ +1.5%
2022 0.99x CN¥149.82 Million CN¥150.80 Million ▲ +7.9%
2021 0.92x CN¥96.20 Million CN¥104.48 Million ▼ -27.8%
2020 1.27x CN¥121.82 Million CN¥95.55 Million ▲ +64.7%
2019 0.77x CN¥64.08 Million CN¥82.78 Million ▼ -43.3%
2018 1.36x CN¥89.12 Million CN¥65.30 Million ▼ -23.3%
2017 1.78x CN¥113.47 Million CN¥63.73 Million ▲ +92.0%
2016 0.93x CN¥60.10 Million CN¥64.80 Million
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.